Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

An updated look at the risk of heart damage associated with 2 popular COVID-19 vaccines

The risk of developing vaccine-related myocarditis, pericarditis or myopericarditis remains very low, researchers wrote. 

ECMO unit in service at Banner Medical Center in Phoenix.

Early use of ECMO fails to improve cardiogenic shock outcomes, surprising cardiologists

"We expected to see a significant improvement in outcomes for patients with severe or rapidly progressing cardiogenic shock who underwent early ECMO treatment," one specialist said. 

Thumbnail

AI-powered ECG screening boosts patient outcomes—when clinicians give it a chance

New research out of Mayo Clinic found that clinicians who listened to AI-based treatment recommendations were more successful at identifying patients with low ejection fraction. 

David Bennett with two of his physical therapists at the University of Maryland Medical Center

ECG data from historic pig heart transplant surprise electrophysiologists

“This was a true milestone for research on xenotransplantation," one specialist said. The full analysis is scheduled to be presented at the American Heart Association's Scientific Sessions 2022 in Chicago.

Abiomed’s Impella RP Flex with SmartAssist heart pump has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute right heart failure for up to 14 days.

Abiomed heart pump gains FDA approval to treat acute right heart failure

The device includes dual-sensor technology, an 11 French indwelling catheter and a flexible cannula.

Thumbnail

Dapagliflozin still beneficial for HFpEF, HFmrEF patients with AFib

While some heart failure medications are less effective in patients with concomitant atrial fibrillation, new research suggests that is not the case for dapagliflozin.

Regulatory Roundup: FDA approves new heart failure therapy, clears an interventional device and much more

The FDA has been busy this month. Review some of the biggest FDA-related stories of October, including big news from scPharmaceuticals, Abiomed, Bristol Myers Squibb and MedAlliance, in our monthly roundup. 

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

Researchers awarded $31M to study conduction system pacing among heart failure patients

“Once the study begins, it will likely be one of the largest heart pacing clinical trials happening in the world over the next few years," one specialist said. 

Displaying 185 - 192 of 645
Design by Adaptive Theme